IAG’s Team published a new article ‘Artificial intelligence-based Clinical Decision Support systems using advanced medical imaging & Radiomics’, Elsevier’s Current Problems in Diagnostic Radiology, June 2020
Image Analysis Group, demonstrates its thought leadership in the field of radiomics through its recently published article in Elsevier’s “Current Problems in Diagnostic Radiology”. This comprehensive review highlights how radiomics, powered by artificial intelligence (AI), is transforming clinical decision support systems in medicine.
Key aspects of radiomics application in clinical decision support:
-
Quantitative Feature Extraction: Radiomics involves high-throughput computation of quantitative features from medical images, providing a more comprehensive tissue description than traditional parameters.
-
AI-Driven Analysis: Machine learning and deep learning techniques analyze these extracted features, creating sophisticated computer-aided diagnostic systems and predictive models.
-
Multimodal Integration: Radiomics features can be integrated with clinical data and other biomarkers to create comprehensive predictive models, enhancing diagnostic accuracy.
-
Personalized Medicine: By correlating radiomic signatures with treatment outcomes, these advanced analytical methods guide personalized treatment strategies, particularly in oncology.
-
Workflow Optimization: AI-powered radiomics systems can automate image processing, detect anomalies, and provide decision-support resources, improving efficiency in clinical workflows.
-
Clinical Trial Enhancement: Radiomics can optimize patient stratification in clinical trials, potentially accelerating drug development processes.
-
Predictive Modeling: Machine learning in radiomics improves predictive modeling, allowing for more accurate prognosis and treatment response predictions.
IAG’s Dynamika™ platform exemplifies the practical application of these concepts, offering life sciences companies a powerful tool to de-risk clinical development and accelerate the delivery of life-saving therapies.
While radiomics shows immense promise, challenges remain in standardization, reproducibility, and clinical integration. IAG’s thought leadership in addressing these challenges positions the company at the forefront of translating radiomics into clinically applicable tools, potentially revolutionizing patient care and drug development.